Answers are grounded in this paper and cite their sources.
Fusarium oxysporum is a major plant pathogen, and marine macroalgae are promising sources of natural antifungal metabolites, yet the antifungal potential of Dictyota dichotoma remains largely unexplored. This study evaluated the in vitro activity of a Dictyota dichotoma aqueous extract, obtained by pressurized hot-water extraction (PHWE), against Fusarium oxysporum, characterized its metabolomic profile by untargeted nanoLC-MS/MS, and explored in silico the interactions of four putatively annotated metabolites (chlorogenic acid, quercetin, epicatechin, isorhamnetin-3-O-glucoside) with sterol 14α-demethylase (CYP51), using CYP51B from Aspergillus fumigatus (PDB 6CR2) as a structural model. The extract inhibited mycelial growth in a concentration-dependent manner (0.5–15 mg/mL), reaching 79.63 ± 0.63% at 15 mg/mL (IC50 = 3.75 mg/mL; 95% CI: 3.51–3.82), with tebuconazole as a positive control. It contained 2.28 ± 0.05 mg GAE/g dry weight of total phenolics, 1.62 ± 0.04 mg QE/g of flavonoids, and 0.81 ± 0.03 mg CE/g of condensed tannins. Docking scores ranged from −10.0 to −8.8 kcal/mol (tebuconazole: −11.5 kcal/mol; redocking RMSD: 0.901 Å). These results support Dictyota dichotoma as a source of antifungal compounds and illustrate the value of combining bioassay, metabolomics, and docking. The predicted interactions are hypothesis-generating and do not prove enzymatic inhibition; experimental validation is required.
No takes yet. Share an insight, caveat, or question.
Senhaji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: